Wang Yunze, Han Lizhu, Zhang Wei, Sun Jing
College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, China.
Medicine (Baltimore). 2020 Nov 13;99(46):e22830. doi: 10.1097/MD.0000000000022830.
Since December 2019, COVID-19, caused by the new coronavirus (SARS-CoV-2), posed a serious threat to human health. On March 11, 2020, the World Health Organization announced that COVID-2019 has become a global pandemic. In China, Reduning injection (REDI) and Xuanfeibaidu formula (XFF) is widely used in treating COVID-19. However, there is no evidence-based medical evaluation that XFF combine with REDI is effective for COVID-19.
The following databases will be searched: China National Knowledge Infrastructure (CNKI), Wanfang database, Chinese Science and Technology Periodical Database, Medline/PubMed, and Cochrane from October 1, 2019 to September 1, 2020. The suitable articles will be comprehensively and systematically searched without limitations of regions or language about REDI with XFF for COVID-19. The meta-analysis was performed by RevMan 5.3 and STATA 14.2 software.
This meta-analysis may help provide clarify on the effect of REDI combined with XFF to treat COVID-19. The result will be published at a peer-reviewed journal.
This systematic review aims to provide new evidence of XFF combined with REDI for the treatment of COVID-19 in terms of its efficacy and safety.
INPLASY202090039.
自2019年12月以来，新型冠状病毒（SARS-CoV-2）引起的COVID-19对人类健康构成了严重威胁。2020年3月11日，世界卫生组织宣布COVID-19已成为全球大流行疾病。在中国，热毒宁注射液（REDI）和宣肺败毒方（XFF）被广泛用于治疗COVID-19。然而，尚无循证医学评估表明XFF联合REDI对COVID-19有效。
检索以下数据库：中国知网（CNKI）、万方数据库、中国科技期刊数据库、Medline/PubMed以及Cochrane数据库，检索时间为2019年10月1日至2020年9月1日。将全面、系统地检索关于REDI联合XFF治疗COVID-19的合适文章，不受地区或语言限制。采用RevMan 5.3和STATA 14.2软件进行荟萃分析。
本荟萃分析可能有助于阐明REDI联合XFF治疗COVID-19的效果。结果将在同行评审期刊上发表。
本系统评价旨在为XFF联合REDI治疗COVID-19的有效性和安全性提供新的证据。
国际系统评价注册平台（INPLASY）注册号：INPLASY202090039。
